


**Barcelona
London Day[®]**

**Life Science Sector
Trends and Opportunities**

Catalonia/Barcelona: a Growing innovation hub in Europe



INNOVATION IN CITIES AROUND THE WORLD, 2017
Position of Barcelona



During the first semester of 2018, 17 multinationals announced new innovation set-ups in Catalonia.

amazon

facebook

Microsoft

SIEMENS

Allianz

ORACLE



moodle



SATELLOGIC

Catalonia is one of the leading scientific hubs in Europe



The ecosystem, accounting for 1,060 companies and 89 research institution, including research centres, universities and university hospitals, is a very powerful research and innovation health hub competing internationally: It ranks #3 in ERC Grants in Europe, after Sweden and Belgium



The hub is also very significant in terms of GDP generation and employment: 223,000 people employed and over 7% of Catalonia's GDP



Catalonia is one of the leading scientific hubs in Europe




Barcelona is #34 in science output worldwide (and #8 in Europe)




Source: Nature index 2018 Science Cities; Figures in the graph represent the fractional count (FC), which takes into account

Nature + Science



ERC Grants




Sources: AGAUR (2007-March 2018); Web of Science (2013-2017)

Funding raised is on Upward trend, highlighting private investment



Investment in startups, in €M




Source: Biocat

Number of International Investors

50

International investors

(x10 in just 5 years)



Japan
Russia
United Kingdom
Norway
Mexico
Luxembourg
Italy
Israel
Ireland
Canada
China
Germany
Austria
Switzerland
France
Belgium
Netherlands
United States

Life Science Sector: Trends and opportunities























































Key sector Features

- Top city in innovation in many areas such as life sciences, technologies, materials, internet, Artificial Intelligence
- Top science (#8 in Europe Nature Index, BEFORE Copenhagen, Vienna, Stockholm)
- Everything at a walking distance (Unis, Research, Hosps, Business Schools, Innovation Centers, SuperComputer, etc)
- Great opportunity for investment in life sciences: strong ecosystem and nascent companies
- Highly skilled talent available (pharma, biotech, entrepreneurs, regulatory, clinical trials)
- High capacity in clinical trials execution
- Barcelona: the perfect place to maximize the use of capital (reasonable pre-money valuations, reasonable costs for execution, same end value as anywhere else in the world)
- And most importantly: we share values with Europe (democracy, working ethics, honesty, excellence)

Case studies:

- M&A Stat-Diagnostica to Quiagen
- Minoryx raising significant Series B
- Barcelona to host BioEquity

Life Science Sector: Trends and opportunities

	2015	2016	2017	2018
€11-50 M Invested	 	   	 	 
€1-10 M Invested	        	           	            	       

Mediktor Raises \$3.4M in Series A Funding

Mediktor, a Barcelona-based biotech company, has announced that it has raised \$3.4 million in Series A funding. The round was led by the company's existing investors, including the Spanish government and the European Union. The funding will be used to advance the company's pipeline of drugs for the treatment of Alzheimer's disease and Parkinson's disease.

Mediktor is a biotech company focused on the development of drugs for the treatment of neurodegenerative diseases. The company's pipeline includes several drugs in various stages of clinical development. The company's most advanced drug, AMBAR, is a small molecule that targets the amyloid-beta protein, which is a key player in the development of Alzheimer's disease. AMBAR has shown promising results in preclinical studies and is currently in phase 1 clinical trials. The company's other drugs are also in various stages of development.

Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

Grifols presents AMBAR (Alzheimer Management by Albumin Replacement) top line results (phase IIb/III) at the 'Clinical Trials on Alzheimer's Disease' (CTAD) congress on October 27, 2018 in Barcelona.

AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients.

NEWS PROVIDED BY Grifols
Oct 27, 2018, 03:30 ET

BARCELONA, Spain, Oct. 27, 2018 (PRNewswire) -- Presenting the study results, Antonio D.

Orizon raises €13 million through a private US and European investors

Orizon, a biotech company, has announced that it has raised €13 million in private funding. The round was led by the company's existing investors, including the Spanish government and the European Union. The funding will be used to advance the company's pipeline of drugs for the treatment of Alzheimer's disease and Parkinson's disease.

Orizon is a biotech company focused on the development of drugs for the treatment of neurodegenerative diseases. The company's pipeline includes several drugs in various stages of clinical development. The company's most advanced drug, AMBAR, is a small molecule that targets the amyloid-beta protein, which is a key player in the development of Alzheimer's disease. AMBAR has shown promising results in preclinical studies and is currently in phase 1 clinical trials. The company's other drugs are also in various stages of development.

FierceBiotech

BIOTECH RESEARCH CRO MEDTECH

Roche-backed Minoryx raises €21M to expand CNS R&D

by Nick Paul Taylor | Sep 26, 2018 8:50am

Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.

Spain's Minoryx established itself as an emerging player in neurodegeneration R&D in 2015 when it raised a €19.4 million series A round to take PPAR-gamma agonist MIN-102 into clinical trials. Three years later, Minoryx has advanced MIN-102 into a phase 2/3 trial in patients with the inherited spinal cord condition adrenomyeloneuropathy.

FierceBiotech

BIOTECH RESEARCH CRO MEDTECH

Orizon raises €13M through private US and European investors

Orizon, a biotech company, has announced that it has raised €13 million in private funding. The round was led by the company's existing investors, including the Spanish government and the European Union. The funding will be used to advance the company's pipeline of drugs for the treatment of Alzheimer's disease and Parkinson's disease.

Orizon is a biotech company focused on the development of drugs for the treatment of neurodegenerative diseases. The company's pipeline includes several drugs in various stages of clinical development. The company's most advanced drug, AMBAR, is a small molecule that targets the amyloid-beta protein, which is a key player in the development of Alzheimer's disease. AMBAR has shown promising results in preclinical studies and is currently in phase 1 clinical trials. The company's other drugs are also in various stages of development.

Why Barcelona



Strategic location and market potential

- Strategic location: the capital of the Mediterranean sea.
- Market potential: Barcelona metropolitan area with circa 5M people, is the gate way to Southern Europe.
- Good international connections by sea, air and roads.
- Solid Infrastructure.
- Unique quality of life.

Competitiveness in costs

- Average salary level is in the lower to mid range among the most developed cities.
- Office and industrial rental prices are competitive, compared to other European cities.
- Housing is still cheaper than main European capitals.

Well positioned to generate and attract talent

- High quality education system with internationally ranked business schools: IESE and ESADE.
- The city is a talent magnet for internationals. 18.5% of the population are foreigners. The international talent attracted by the high quality standards and the interesting job offers, reinforced by the growing digital and tech ecosystem.

Tech, Digital and Knowledge Focus

- Diversified economy and traditionally very entrepreneurial.
- Growing startup hub: with 1,100 tech startups as the 5th European startup hub. In tech entrepreneurship, Barcelona is the 3rd most attractive city to set up a startup, after Berlin and London.

* The area of Barcelona accounts for a 14% of the total Spanish GDP, Catalonia accounts for a 19%.

**Sources:**

- Observatori Barcelona 2018 Report
- Barcelona Data Sheet 2018
- BioCat website and Biocat Report 2017

Diagonal 579
Barcelona 08014
+34 936 761 250
barcelonaglobal@barcelonaglobal.org
barcelonaglobal.org
[@barcelonaglobal](https://www.instagram.com/barcelonaglobal)

**Barcelona
London Day[®]**

For further information:

makeithappen@barcelonaglobal.org



**Barcelona
Global**